Hereditary breast cancer in Jews

Familial Cancer

Volumn 3, Issue 3-4, 2004, Pages 249-257

  Rubinstein, Wendy ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BRCA2, breast neoplasms; breast neoplasms male; founder effect; genetic predisposition to disease; genetic screening; Jews; penetrance; prevalence

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; ERROR; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; GENOTYPE; HETEROZYGOTE; HUMAN; JEW; PREVALENCE; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INCIDENCE; JEWS; MALE; MIDDLE AGED; PEDIGREE; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; UNITED STATES;

EID: 8544275871     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10689-004-9550-2     Document Type: Article

References (110)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8-29.
2. Rubinstein WS, O'Neill SM. Quantitative Risk Assessment. Advanced Therapy of Breast Disease. New York: BC Decker 2004.
3. Struewing JP, Abeliovich D, Peretz T et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 1995; 11 (2): 198-200.
4. Friedman LS, Szabo CI, Ostermeyer EA et al. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. Am J Hum Genet 1995; 57 (6): 1284-97.
5. Tonin P, Serova O, Lenoir G et al. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 1995; 57 (1): 189.
6. Berman DB, Wagner-Costalas J, Schultz DC et al. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. Am J Hum Genet 1996; 58 (6): 1166-76.
7. Berman DB, Costalas J, Schultz DC et al. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 1996; 56 (15): 3409-14.
8. Fitzgerald MG, MacDonald DJ, Krainer M et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996; 334 (3): 143-9.
9. Neuhausen S, Gilewski T, Norton L et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996; 13 (1): 126-8.
10. Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14 (2): 185-7.
11. Oddoux C, Struewing JP, Clayton CM et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996; 14 (2): 188-90.
12. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266 (5182): 66-71.
13. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 (6559): 789-92.
14. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12 (3): 333-7.
15. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 1995; 57 (6): 1457-62.
16. Lynch HT, Marcus JN, Lynch JF et al. Breast cancer genetics: heterogeneity, molecular genetics, and syndrome diagnosis, and genetics counseling. In Bland and Copeland (eds): The Breast. Amsterdam: Elsevier 2004: 375-411.
17. Richards CS, Ward PA, Roa BB et al. Screening for 185delAG in the Ashkenazim. Am J Hum Genet 1997; 60 (5): 1085-98.
18. Lehmann LS, Weeks JC, Klar N, Garber JE. A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing. Genet Med 2002; 4 (5): 346-52.
19. Foulkes WD, Wong N, Brunet JS et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 1997; 3 (12 Pt 1): 2465-9.
20. Robson ME, Chappuis PO, Satagopan J et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004; 6 (1): R8-R17.
21. Narod SA, Brunet JS, Ghadirian P et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356 (9245): 1876-81.
22. Ozcelik H, Schmocker B, Di Nicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 1997; 16 (1): 17-8.
23. Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94 (23): 1773-9.
24. Narod SA. Modifiers of risk of hereditary breast and ovarian cancer. Nat Rev Cancer 2002; 2 (2): 113-23.
25. Jernstrom H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999; 354(9193): 1846-50.
26. Hartge P, Chatterjee N, Wacholder S et al. Breast cancer risk in Ashkenazi BRCA1/2 mutation carriers: effects of reproductive history. Epidemiology 2002; 13 (3): 255-61.
27. Quenneville LA, Phillips KA, Ozcelik H et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002; 95 (10): 2068-75.
28. Levy-Lahad E, Lahad A, Eisenberg S et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 2001; 98 (6): 3232-6.
29. Kadouri L, Kote-Jarai Z, Easton DF et al. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int J Cancer 2004; 108 (3): 399-403.
30. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336 (20): 1401-08.
31. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302 (5645): 643-6.
32. Lynch HT, Snyder CL, Lynch JF et al. Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. J Clin Oncol 2003; 21 (4): 740-53.
33. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21 (12): 2397-2406.
34. Newman B, Austin MA, Lee M, King MC. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families. Proc Natl Acad Sci USA 1988; 85 (9): 3044-8.
35. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250 (4988): 1684-9.
36. Online Mendelian Inheritance in Man. Retrieved from http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db = OMIM on 15 March 2004.
37. Breast Cancer Information Core (BIC). National Human Genome Research Institute. Retrieved from http://research.nhgri.nih.gov/bic/ on 15 March 2004.
38. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997; 60 (5): 1013-20.
39. Frank TS, Deffenbaugh AM, Reid JE et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002; 20 (6): 1480-90.
40. Kauff ND, Perez-Segura P, Robson ME et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet 2002; 39(8): 611-4.
41. Liede A, Metcalfe K, Offit K et al. A family with three germline mutations in BRCA1 and BRCA2. Clin Genet 1998; 54 (3): 215-8.
42. Friedman E, Bar-Sade BR, Kruglikova A et al. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet 1998; 63 (4): 1224-7.
43. Newill VA. Distribution of cancer mortality among etimic subgroups of the white population of New York City, 1953-58. J Natl Cancer Inst 1961; 26: 405-17.
44. Salber EJ, Trichopulos D, MacMahon B. Lactation and reproductive histories of breast cancer patients in Boston, 1965-66. J Natl Cancer Inst 1969; 43 (5): 1013-24.
45. Egan KM, Newcomb PA, Longnecker MP et al. Jewish religion and risk of breast cancer. Lancet 1996; 347 (9016): 1645-6.
46. Toniolo PG, Kato I. Jewish religion and risk of breast cancer. Lancet 1996; 348 (9029): 760.
47. Jews and Medicine. Philadelphia/ Jerusalem: The Jewish Publication Society, 1995.
48. Narod SA, Goldgar D, Cannon-Albright L et al. Risk modifiers in carriers of BRCA1 mutations. Int J Cancer 1995; 64 (6): 394-8.
49. Chang-Claude J, Becher H, Eby N et al. Modifying effect of reproductive risk factors on the age at onset of breast cancer for German BRCA1 mutation carriers. J Cancer Res Clin Oncol 1997; 123 (5): 272-9.
50. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72 (5): 1117-30.
51. Chatterjee N, Shih J, Hartge P et al. Association and aggregation analysis using kin-cohort designs with applications to genotype and family history data from the Washington Ashkenazi Study. Genet Epidemiol 2001; 21 (2): 123-38.
52. Rutter JL, Chatterjee N, Wacholder S, Struewing J. The HER2 I655V polymorphism and breast cancer risk in Ashkenazim. Epidemiology 2003; 14 (6): 694-700.
53. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993; 53 (4): 538-49.
54. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002; 137 (8): 678-87.
55. Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer 1999; 86 (5): 744-6.
56. Ford D, Easton DF, Stratton M et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62 (3): 676-89.
57. Steinitz R, Katz L, Ben Hur M. Male breast cancer in Israel: selected epidemiological aspects. Isr J Med Sci 1981; 17 (9-10): 816-21.
58. Brenner B, Fried G, Levitzki P et al. Male breast carcinoma in Israel: higher incident but possibly prognosis in Ashkenazi Jews. Cancer 2002; 94 (8): 2128-33.
59. Friedman LS, Gayther SA, Kurosaki T et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997; 60 (2): 313-9.
60. Couch FJ, Farid LM, DeShano ML et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996; 13 (1): 123-5.
61. Thorlacius S, Sigurdsson S, Bjarnadottir H et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet 1997; 60 (5): 1079-84.
62. Struewing JP, Coriaty ZM, Ron E et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet 1999; 65 (6): 1800-02.
63. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 2004; 22 (4): 735-42.
64. Easton DF, Steele L, Fields P et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997; 61 (1): 120-8.
65. Liede A, Metcalfe K, Hanna D et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 2000; 67 (6): 1494-504.
66. Shattuck-Eidens D, Oliphant A, McClure M et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA 1997; 278 (15): 1242-50.
67. Couch FJ, DeShano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997; 336 (20): 1409-15.
68. Frank TS, Manley SA, Olopade OI et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1998; 16 (7): 2417-25.
69. Rubinstein WS, O'Neill SM, Peters JA et al. Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine. Oncology (Huntingt) 2002; 16 (8): 1082-94.
70. Bahar AY, Taylor PJ, Andrews L et al. The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer 2001; 92 (2): 440-5.
71. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 1997; 60 (3): 496-504.
72. Andersen TI. Genetic heterogeneity in breast cancer susceptibility. Acta Oncol 1996; 35 (4): 407-10.
73. Peto J, Collins N, Barfoot R et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999; 91 (11): 943-9.
74. Hartge P, Struewing JP, Wacholder S et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 1999; 64 (4): 963-70.
75. Krainer M, Silva-Arrieta S, Fitzgerald MG et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med 1997; 336 (20): 1416-21.
76. Fodor FH, Weston A, Bleiweiss IJ et al. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 1998; 63 (1): 45-51.
77. Warner E, Foulkes W, Goodwill P et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999; 91 (14): 1241-7.
78. Abeliovich D, Kaduri L, Lerer I et al. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 1997; 60(3): 505-14.
79. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56 (1): 265-71.
80. Levy-Lahad E, Catane R, Eisenberg S et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997; 60 (5): 1059-67.
81. Thorlacius S, Struewing JP, Hartge P et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352 (9137): 1337-9.
82. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer 2000; 83 (10): 1301-8.
83. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68(3): 700-10.
84. Satagopan JM, Offit K, Foulkes W et al. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 2001; 10 (5): 467-73.
85. Brose MS, Rebbeck TR, Calzone KA et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002; 94 (18): 1365-72.
86. Foulkes WD, Brunet JS, Wong N et al. Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study. J Med Genet 2002; 39 (6): 407-9.
87. Satagopan JM, Boyd J, Kauff ND et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002; 8 (12): 3776-81.
88. Hopper JL, Southey MC, Dite GS et al. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999; 8 (9): 741-7.
89. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2002; 94 (16): 1221-6.
90. Gong G, Whittemore AS. Optimal designs for estimating penetrance of rare mutations of a disease-susceptibility gene. Genet Epidemiol 2003; 24 (3): 173-80.
91. Gail MH, Pee D, Benichou J, Carroll R. Designing studies to estimate the penetrance of an identified autosomal dominant mutation: cohort, case-control, and genotyped-proband designs. Genet Epidemiol 1999; 16 (1): 15-39.
92. Wacholder S, Hartge P, Struewing JP et al. The kin-cohort study for estimating penetrance. Am J Epidemiol 1998; 148 (7): 623-30.
93. Amos CI. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003; 95 (1): 74-5.
94. Pharoah PDP, Antoniou A, Hopper J, Easton D. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003; 95 (1): 75-6.
95. Whittemore AS, Gong G. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003; 95 (1): 76-7.
96. Begg CB. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003; 95 (1): 77-8.
97. Burke W, Austin M. On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 2003; 95 (1): 78-9.
98. Frezzo TM, Rubinstein WS, Dunham D, Ormond KE. The genetic family history as a risk assessment tool in internal medicine. Genet Med 2003; 5 (2): 84-91.
99. Reynolds T. Study clarifies risk of breast, ovarian cancer among mutation carriers. J Natl Cancer Inst 2003; 95 (24): 1816-8.
100. de Sanjose S, Leone M, Berez V et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer 2003; 106 (4): 588-93.
101. Principles of Screening: Report of The Subcommittee on Screening of the American College of Medical Genetics Clinical Practice Committee. 20 March 0004.
102. Schwartz MD, Peshkin BN, Hughes C et al. Impact of BRCA1/ BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002; 20 (2): 514-20.
103. Peterson EA, Milliron KJ, Lewis KE et al. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002; 11 (1): 79-87.
104. Armstrong K, Weber B, FitzGerald G et al. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet 2003; 120A (3): 359-64.
105. Hall MA, Rich SS. Patients' fear of genetic discrimination by health insurers: the impact of legal protections. Genet Med 2000; 2 (4): 214-21.
106. Hall MA, Rich SS. Laws restricting health insurers' use of genetic information: impact on genetic discrimination. Am J Hum Genet 2000; 66 (1): 293-307.
107. Grann VR, Whang W, Jacobson JS et al. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 1999; 17 (2): 494-500.
108. Lawrence WF, Peshkin BN, Liang W et al. Cost of genetic counseling and testing for BRCA1 and BRCA2 breast cancer susceptibility mutations. Cancer Epidemiol Biomarkers Prev 2001; 10(5): 475-81.
109. Tercyak KP, Peshkin BN, Streisand R, Lerman C. Psychological issues among children of hereditary breast cancer gene (BRCA1/2) testing participants. Psychooncology 2001; 10 (4): 336-46.
110. Hughes C, Lerman C, Schwartz M et al. All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 2002; 107 (2): 143-50.